CLDN6 and neoplasm: The results showed that the higher expression of CLDN6 had a worse OS in most clinical subgroups, including subgroup of age > 60 (Figure 7A), subgroup of weight > 80 (Figure 7B), subgroup of BMI > 30 (Figure 7C), subgroup of tumor invasion ≥ 50% (Figure 7D), subgroup of postmenopause (Figure 7E), subgroup of primary therapy outcome (CR) (Figure 7F), subgroup of residual tumor (R0) (Figure 7G), subgroup of radiation therapy (No) (Figure 7H), and subgroup of diabetes (No) (Figure 7I).